AYTU: Aytu BioPharma, Inc. Stock

by  •  • Comments Off on AYTU: Aytu BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.90
Enterprise Value ($M) 3.35
Book Value ($M) 30.77
Book Value / Share 4.99
Price / Book 0.26
NCAV ($M) -22.41
NCAV / Share -3.63
Price / NCAV -0.35

Profitability (mra)
Return on Invested Capital (ROIC) -0.11
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.16

Liquidity (mrq)
Quick Ratio 0.81
Current Ratio 0.98

Balance Sheet (mrq) ($M)
Current Assets 63.05
Assets 116.23
Liabilities 85.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 81.00
Operating Income -2.16
Net Income -15.84
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.39
Cash from Investing -0.33
Cash from Financing -1.26

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-13 13G/A Stonepine Capital Management, LLC 9.99 10.85
06-18 13D/A Nantahala Capital Management, LLC 18.20 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 5,693 58,863 9.67
2025-03-06 9,924 32,408 30.62
2025-03-05 14,547 91,168 15.96
2025-03-04 4,378 32,697 13.39

(click for more detail)

Similar Companies
ATYR – aTyr Pharma, Inc. AVTX – Avalo Therapeutics, Inc.
AWH – Aspira Women's Health Inc. BCDA – BioCardia, Inc.
BCLI – Brainstorm Cell Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io